Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
ABSTRACT
The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵# Joint first authors
Subject Area
- Biochemistry (11703)
- Bioengineering (8718)
- Bioinformatics (29127)
- Biophysics (14930)
- Cancer Biology (12048)
- Cell Biology (17353)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18266)
- Genetics (12219)
- Genomics (16765)
- Immunology (11841)
- Microbiology (28003)
- Molecular Biology (11551)
- Neuroscience (60804)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3229)
- Physiology (4939)
- Plant Biology (10383)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)